Drug Target Review

DECEMBER 28, 2023

During the process of transformation from a normal cell into a cancer cell, a cell acquires a series of changes, or mutations, in its DNA. But DNA mutations can also result in changes to the proteins that are displayed on the surface of the cancer cell.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

KIF1A

MAY 4, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. By talking to groups with these mutations, we may identify other diseases whose patients have KIF1A variants. She graduated from UC San Diego with a B.S.

Science 116

Science Medical Schools RNA Research 116

New Drug Approvals

SEPTEMBER 23, 2024

Target: DNA/RNA Synthesis Pathway: Cell Cycle/DNA Damage Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. SCHEME PATENT PTC Therapeutics Inc., Audiol Res. 2020-01-02.

Small Molecule 57

Small Molecule RNA DNA Disease 57

PLOS: DNA Science

JUNE 1, 2023

This DNA Science post from 2018 traces the history of the efforts. Peter Marinkovich, MD, director of the Blistering Disease Clinic at Stanford Health Care, calls DEB a devastating disease. RDEB is inherited from two carrier parents. DEB has been a candidate for a gene therapy since 2002. Primary investigator M.

FDA Approval 52

FDA Approval Therapies FDA Disease 52

New Drug Approvals

SEPTEMBER 29, 2024

gingivalis has been called a risk factor for Alzheimer’s disease ( Kanagasingam et al., gingivalis DNA was detected in postmortem cortices from people with AD and healthy controls, and in CSF of AD patients ( Jan 2019 news on Dominy et al., 2018 ; Ding et al., gingivalis is associated with cardiovascular disease.

Small Molecule 62

Small Molecule DNA Disease Trials 62

Broad Institute

JULY 10, 2023

Credit: Allison Colorado, Broad Communications Arriving in the Bay Area after a childhood in increasingly diverse surroundings, Martin became acutely aware of health disparities and the profound differences in disease prevalence among different populations. I wanted to know how I could have any impact on studying genetic diversity.”

Bioinformatics 98

Bioinformatics Disease Medical Schools Research 98

Drug Target Review

NOVEMBER 6, 2023

Advances in disease understanding and combination strategies in haematology We now know that blood cancers are characterised by molecular and phenotypic heterogeneity. Published 2018 Nov 13. 2 It is this complexity that necessitates powerful, targeted combination therapies. Available at: [link] Accessed October 2023. Front Pharmacol.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

The Pharma Data

SEPTEMBER 3, 2020

The technology could one day prevent parents from passing on heritable diseases to children, but the committee says much more research is needed. The world’s first gene-edited babies were born in China in November 2018. One example of current technology is CRISPR, a biological system for altering DNA discovered in 2012.

DNA 52

DNA International Science Disease 52

Broad Institute

MAY 2, 2024

In 2018, she graduated with a bachelor’s degree in computer science and biology and joined the lab of Gad Getz at the Broad Institute of MIT and Harvard to complete her master’s. If we can understand how those processes work, we can better develop drugs to target these multifaceted diseases. What do you like about rowing?

Science 124

Science Medical Schools Disease Hospitals 124

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. 1 , 33–43 (2018).

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

APRIL 3, 2024

Everything started in school with an experiment on isolating DNA from bananas. Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences.

Science 105

Science Clinical Development Treatment DNA 105

Broad Institute

JULY 25, 2024

By Allessandra DiCorato July 25, 2024 Credit: Maria Nemchuk, Broad Communications Ralda Nehme When Ralda Nehme, a cell biologist and neuroscientist, first started her lab at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard in 2018, she realized a gap in the field.

Clinical Trials 75

Clinical Trials Disease DNA Trials 75

The Pharma Data

MAY 18, 2021

MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. This companion diagnostic (CDx) provides clinicians with a standardised testing option that uses a comprehensive panel of DNA mismatch repair (MMR) biomarkers tested by immunohistochemistry (IHC).

FDA Approval 40

FDA Approval FDA DNA Therapies 40

DrugBank

JUNE 27, 2023

Out of the millions of genetic variants present in human populations, GWAS are designed to uncover those associated with specific traits or diseases. 9 Polygenic diseases are much more common, and thousands of genetic variants with very small effects could impact their phenotype.

Disease 88

Disease Treatment Drugs Clinical Trials 88

NIH Director's Blog: Drug Development

MAY 15, 2018

Credit: National Institute of Allergy and Infectious Diseases, NIH As a volunteer physician in a small hospital in Nigeria 30 years ago, I was bitten by lots of mosquitoes and soon came down with headache, chills, fever, and muscle aches. In 2016 alone, an estimated 216 million people were treated for the disease. 18 January 2018. [2]

Drug Development 52

Drug Development Drugs Disease Treatment 52

The Pharma Data

NOVEMBER 24, 2020

Currently, mCRPC remains an incurable disease, and despite advancements in available therapies, the 5 year survival rate for men with metastatic prostate cancer is only 28 per cent. . Prostate cancer is the most common cancer among Canadian men, and the third leading cause of cancer deaths amongst this demographic.

Treatment 52

Treatment DNA Trials Therapies 52

Drug Target Review

JANUARY 22, 2024

Pioneer TFs can recognise their target DNA sequences in compacted heterochromatin and can trigger remodelling of the adjoining chromatin landscape to provide accessibility to nonpioneer TFs. 2018 September [2024 January 15]; 293(36):13795-804. This study was published in Molecular Cell. References 1 Drouin J, Mayran A.

DNA 59

DNA Engineering Hospitals Research 59

The Pharma Data

DECEMBER 2, 2020

Onivyde, in combination with fluorouracil and leucovorin, was previously approved for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E.

Licensing 52

Licensing Licensing DNA Vaccine 52

Drug Target Review

JUNE 19, 2024

The other powerful benefit is that our cell lines can become any of the cell types of the human body – these cells have within their DNA the capability to become any of the more than 200 human cell types which you might want to manufacture. This provides some regulatory advantages, and of course, significant cost advantages.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

PLOS: DNA Science

SEPTEMBER 21, 2023

In addition to rare genetic diseases, talks at the Festival will address Crohn’s disease, rheumatoid arthritis, polycystic ovarian syndrome, and neurological disease and cancers. What steps should researchers take when attempting to acquire DNA samples from modern descendants? From people who have died?”

DNA 52

DNA Science Medical Schools Government 52

The Pharma Data

JUNE 28, 2021

Bayer is focused on addressing the various medical needs of cancer patients, providing treatments that improve patient outcomes throughout the different stages of the disease,” said Robert LaCaze, Member of the Executive Committee of the Pharmaceuticals Division and Head of the Oncology Strategic Business Unit at Bayer.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

Agency IQ

APRIL 19, 2024

FDA advisors endorse minimal residual disease (MRD) as accelerated approval endpoint for multiple myeloma Last week, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously in favor of using minimal residual disease (MRD) as an accelerated approval endpoint for multiple myeloma.

FDA 40

FDA Disease Trials Clinical Trials 40

Drug Target Review

APRIL 12, 2023

3 Analysing the genome allows patterns to be identified that can help determine individual risk of developing diseases. Nature Publishing Group; 2018 [cited 2023Apr12]. BCG Global; 2023 [cited 2023Apr12]. Available from: [link] Fleming N. How artificial intelligence is changing drug discovery [Internet]. Nature News.

Drugs 52

Drugs DNA Disease Science 52

PLOS: DNA Science

MARCH 30, 2023

The agency launched FungiNet in 2021, as “a network for molecular surveillance and genomic epidemiology for fungal diseases,” with initial focus on C. Comparing genome sequences is important because they provide a 4-letter language in the bases A, C, G, and T (for DNA) or A, C, G, and U (for RNA).

DNA 52

DNA Hospitals Laboratories Virus 52

The Pharma Data

JANUARY 24, 2021

Professor of Medicine, Section of Infectious Diseases and Global Health and director of the Duchossois Family Institute at the University of Chicago, has joined its scientific advisory board. His research focuses on the role of the microbiome in immune defense and disease resistance. “We

Research 40

Research Bioinformatics Laboratories International 40

Codon

NOVEMBER 3, 2024

Physicians working in the early 20th century had little choice but to treat the world’s most rampant infectious disease with methods such as these. But even now, more than a century later, TB remains the deadliest infectious disease on Earth, killing about 1.2 million people every year.

Vaccine 85

Vaccine Trials Therapies Treatment 85

Codon

OCTOBER 13, 2024

The chefs at Farma know that by embracing food technologies such as recombinant DNA, precision fermentation, and cell culture, food can become more nutritious and better for the planet. One of these is “citrus canker,” a bacterial disease that causes the fruits to develop necrotic lesions. In 2018, for example, the U.S.

Engineering 85

Engineering Virus Production DNA 85

Agency IQ

MARCH 29, 2024

FDA’s oncology advisory committee to consider MRD as a multiple myeloma endpoint Yesterday, the FDA announced that its Oncologic Drugs Advisory Committee would weigh in on the potential use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials. immune cells and other blood cell types) lack.

FDA 40

FDA Clinical Trials Treatment Trials 40

The Pharma Data

OCTOBER 14, 2020

Assistant Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons, is designed to generate DNA aptamer-based anti-idiotypes to selected monoclonal antibodies identified in Dr. Ilya Trakht’s study. 2018) PLoS One. The study led by Dr. Sergei Rudchenko, Ph.D., 1 Noyce RS, et al. 13(1):e0188453.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

JUNE 30, 2021

Metastatic colorectal cancer is an aggressive disease with a poor prognosis, leaving patients with a critical need for additional treatment options beyond standard chemotherapy,” said Ian M. The safety profile for Opdivo plus Yervoy was consistent with previous studies of the combination in other tumor types. Waxman, M.D.,

Treatment 52

Treatment Trials FDA Approval Disease 52

Agency IQ

JULY 21, 2023

The next chapter in the ctDNA story: Still promising, not ready for prime time A recent workshop summed up the state of play for circulating tumor DNA. In addition to its use in accelerated approvals, the ORR endpoint has also been used as a surrogate endpoint for traditional approval, the FDA’s 2018 guidance on oncology endpoints notes.

FDA 40

FDA Clinical Trials Treatment DNA 40

The Pharma Data

DECEMBER 27, 2020

This year has been difficult, but it has reinforced the importance of our mission: to treat and potentially even reverse the effects of serious diseases and conditions by advancing our novel cell therapy product candidates through clinical trials and into the hands of physicians.

Therapies 40

Therapies Clinical Trials Production Treatment 40

Codon

JUNE 18, 2024

Dr. Karl Dussik, an Austrian physician, was among the first to suggest that ultrasound could be used to diagnose diseases within the body in 1941. A major breakthrough came in January 2018, when a paper in Nature indicated, for the first time, that gas vesicles could be expressed in E. But ultrasound is different. coli cells.

Engineering 65

Engineering Laboratories International Clinical Trials 65

New Drug Approvals

APRIL 18, 2023

significantly reduces the number of metastatic lung nodules in mice, and lowers the expression of human Alu DNA in mice, without body weight loss [2]. 2018 Jul;40(1):303-308. In Vivo Mavorixafor (AMD-070) (2 mg/kg, p.o.) MCE has not independently confirmed the accuracy of these methods. They are for reference only. Content Brief] [3].

Clinical Trials 52

Clinical Trials Virus Small Molecule Trials 52

Codon

SEPTEMBER 22, 2024

Erasing methyl groups on DNA is necessary for normal egg and sperm development. In 2018, Saitou’s team reported the first method to coax human PGC-like cells into the oogonia stage. The most important step seems to be erasing DNA methylation. At this point, the follicle is ready to release the mature egg.

DNA 96

DNA Laboratories Regulations Therapies 96

The Pharma Data

SEPTEMBER 2, 2021

Susan Galbraith, Executive Vice President, Oncology R&D said: “The DESTINY-Breast03 data at ESMO will demonstrate the potential for Enhertu to transform the treatment of HER2-positive metastatic breast cancer with a safety profile that supports the potential for Enhertu in early-stage disease.

Trials 52

Trials Clinical Trials Therapies Disease 52

Codon

MARCH 14, 2023

They had “seen no evidence of [graft-versus-host disease] in any patient,” wrote surgeon Steven A. There are even differences in how their genomic DNA is packaged inside of neurons. ” Other scientists have said much the same thing since at least 2018. DNA differences accumulate over generations of breeding.

DNA 52

DNA Laboratories Engineering Animal Testing 52